Unknown

Dataset Information

0

Systematic identification of genomic markers of drug sensitivity in cancer cells.


ABSTRACT: Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred cancer cell lines--which represent much of the tissue-type and genetic diversity of human cancers--with 130 drugs under clinical and preclinical investigation. In aggregate, we found that mutated cancer genes were associated with cellular response to most currently available cancer drugs. Classic oncogene addiction paradigms were modified by additional tissue-specific or expression biomarkers, and some frequently mutated genes were associated with sensitivity to a broad range of therapeutic agents. Unexpected relationships were revealed, including the marked sensitivity of Ewing's sarcoma cells harbouring the EWS (also known as EWSR1)-FLI1 gene translocation to poly(ADP-ribose) polymerase (PARP) inhibitors. By linking drug activity to the functional complexity of cancer genomes, systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.

SUBMITTER: Garnett MJ 

PROVIDER: S-EPMC3349233 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Systematic identification of genomic markers of drug sensitivity in cancer cells.

Garnett Mathew J MJ   Edelman Elena J EJ   Heidorn Sonja J SJ   Greenman Chris D CD   Dastur Anahita A   Lau King Wai KW   Greninger Patricia P   Thompson I Richard IR   Luo Xi X   Soares Jorge J   Liu Qingsong Q   Iorio Francesco F   Surdez Didier D   Chen Li L   Milano Randy J RJ   Bignell Graham R GR   Tam Ah T AT   Davies Helen H   Stevenson Jesse A JA   Barthorpe Syd S   Lutz Stephen R SR   Kogera Fiona F   Lawrence Karl K   McLaren-Douglas Anne A   Mitropoulos Xeni X   Mironenko Tatiana T   Thi Helen H   Richardson Laura L   Zhou Wenjun W   Jewitt Frances F   Zhang Tinghu T   O'Brien Patrick P   Boisvert Jessica L JL   Price Stacey S   Hur Wooyoung W   Yang Wanjuan W   Deng Xianming X   Butler Adam A   Choi Hwan Geun HG   Chang Jae Won JW   Baselga Jose J   Stamenkovic Ivan I   Engelman Jeffrey A JA   Sharma Sreenath V SV   Delattre Olivier O   Saez-Rodriguez Julio J   Gray Nathanael S NS   Settleman Jeffrey J   Futreal P Andrew PA   Haber Daniel A DA   Stratton Michael R MR   Ramaswamy Sridhar S   McDermott Ultan U   Benes Cyril H CH  

Nature 20120328 7391


Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred cancer cell lines--which represent much of the tissue-type and genetic diversity of human cancers--with 130 drugs under clinical and preclinical investigation. In aggregate, we found that mutate  ...[more]

Similar Datasets

| S-EPMC5760202 | biostudies-literature
| S-EPMC6096361 | biostudies-other
| S-EPMC6522379 | biostudies-literature
| S-EPMC6700431 | biostudies-literature
| S-EPMC3577103 | biostudies-literature
| S-EPMC9250777 | biostudies-literature
| S-EPMC3304427 | biostudies-other
| S-EPMC2361951 | biostudies-literature
| S-EPMC6828742 | biostudies-literature
| S-EPMC7381100 | biostudies-literature